Skip to main content

Table 1 Patient characterization

From: Accuracy, reliability, feasibility and nurse acceptance of a subcutaneous continuous glucose management system in critically ill patients: a prospective clinical trial

Age

61 [54/69]

Gender (female/male)

14 (70 %)/6 (30 %)

BMI (kg/m2)

23 [22/26]

Diagnosis leading to ICU stay

 

 ARDS (ECMO, ECLA)

6 (30 %)

 ARDS (without ECMO, ECLA)

8 (40 %)

 Mediastinitis

1 (5 %)

 Peritonitis

3 (15 %)

 Intracranial hemorrhage

1 (5 %)

 Polytrauma

1 (5 %)

At least one event of SIRS or sepsis during CGM

20 (100 %)

Sequential organ failure assessment (SOFA) Score at inclusion

8 [4/10]

Acute physiology and chronic health evaluation (APACHE) 2 Score at admission

24 [19/28]

History of diabetes mellitus

5 (25 %)

Administration of intravenous insulin therapy during CGM

14 (70 %)

Administration of vasopressors during CGM

7 (35 %)

Mean dose of epinephrine during sensor running time (µg/kg/min) (in seven patients receiving vasopressors)

0.08 [0.03/0.14]

Mortality during ICU stay

4 (20 %)

  1. n = 20 patients
  2. Results are expressed as median with interquartile range or as absolute numbers with percentages of n = 20 patients
  3. BMI body mass index, ARDS acute respiratory distress syndrome, ECMO extracorporeal membrane oxygenation, ECLA extracorporeal lung assist, SIRS systemic inflammatory response syndrome, SOFA sequential organ failure assessment, APACHE acute physiology and chronic health evaluation, ICU intensive care unit, CGM continuous glucose monitoring